A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates

被引:29
作者
Coban, AY [1 ]
Ekinci, B [1 ]
Durupinar, B [1 ]
机构
[1] Ondokuz Mayis Univ, Tip Fak Mikrobiol, Klin Mikrobiyol Anabilim Dali, Sch Med, TR-55139 Kurupelit, Turkey
关键词
Pseudomonas aeruginosa; fluoroquinolone resistance; efflux pump inhibitor;
D O I
10.1159/000077280
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In general, resistance to fluoroquinolones (FQs) in gram-negative bacteria is acquired either by mutations in DNA gyrase and topoisomerase IV or by active export of the agents via antibiotic efflux pumps. Reduced porin expression is also proposed to be another mechanism leading to resistance. In this study, interaction between levofloxacin, ofloxacin, and ciprofloxacin with MC-207,110 (multidrug efflux pump inhibitor) was investigated by a checkerboard assay using Pseudomonas aeruginosa. Levofloxacin, ofloxacin, and ciprofloxacin were tested at different concentrations (0.06-64 mug/ml) and MC-207,110 was tested at a concentration range of 4 - 128 mug/ml. In the presence of MC-207,110 (at 128, 64, 32, 16 mug/ml) resistance to FQs was inhibited significantly and MIC values were decreased, except at 8 and 4 mug/ml of MC-207,110. When MC-207,110 was used, resistance of P. aeruginosa to FQs in vitro was inhibited significantly, suggesting that MC-207,110 may be useful for use in clinical treatment protocols to overcome FQs resistance. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:22 / 26
页数:5
相关论文
共 23 条
[11]   Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa [J].
Lomovskaya, O ;
Lee, A ;
Hoshino, K ;
Ishida, H ;
Mistry, A ;
Warren, MS ;
Boyer, E ;
Chamberland, S ;
Lee, VJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) :1340-1346
[12]  
Lomovskaya O, 2001, J MOL MICROB BIOTECH, V3, P225
[13]   Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa:: Novel agents for combination therapy [J].
Lomovskaya, O ;
Warren, MS ;
Lee, A ;
Galazzo, J ;
Fronko, R ;
Lee, M ;
Blais, J ;
Cho, D ;
Chamberland, S ;
Renau, T ;
Leger, R ;
Hecker, S ;
Watkins, W ;
Hoshino, K ;
Ishida, H ;
Lee, VJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :105-116
[14]  
National Committee for Clinical Laboratory Standards, 1997, M7A4 NCCLS
[15]   Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis [J].
Piddock, LJV ;
Williams, KJ ;
Ricci, V .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (02) :159-165
[16]   Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria [J].
Poole, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2233-2241
[17]   Multidrug resistance in Gram-negative bacteria [J].
Poole, K .
CURRENT OPINION IN MICROBIOLOGY, 2001, 4 (05) :500-508
[18]   Molecular properties of bacterial multidrug transporters [J].
Putman, M ;
van Veen, HW ;
Konings, WN .
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2000, 64 (04) :672-+
[19]   Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates [J].
Ribera, A ;
Ruiz, J ;
de Anta, MTJ ;
Vila, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (04) :697-U10
[20]   Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and Mycobacterium tuberculosis [J].
Silva, PEA ;
Bigi, F ;
Santangelo, MD ;
Romano, MI ;
Martín, C ;
Cataldi, A ;
Aínsa, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :800-804